Document Detail

Revisiting the role of systemic therapies in patients with metastatic melanoma to the CNS.
MedLine Citation:
PMID:  23617347     Owner:  NLM     Status:  In-Data-Review    
The CNS is a common site of metastasis in patients with malignant melanoma. Locoregional control either with surgery or radiotherapy is first-line treatment for patients with brain metastasis should they be suitable candidates. For those patients who are not and those who progress after previous treatment, there is an unmet clinical need for effective systemic therapies. Systemic cytotoxics, such as temozolamide and fotemustine, have only modest activity, resulting in a median progression-free survival ranging from 1-2 months, in patients with metastatic melanoma to the brain. Newer systemic treatments such as vemurafenib and ipilimumab have been approved for the treatment of melanoma, but evidence regarding their activity in brain metastases is inconclusive due to the limited access of patients to clinical trials. This is now being revised and more data are emerging supporting the inclusion of patients with brain metastasis in trials. In this review, the authors present data regarding the efficacy of systemically administered therapies in patients with metastatic melanoma to the brain.
Dionysis Papadatos-Pastos; Adam Januszewski; Angus Dalgleish
Related Documents :
24088247 - Clinical features and outcomes of neck lymphatic metastasis in ovarian epithelial carci...
23956077 - No benefit in staging fdg-pet in cn0 head and neck cutaneous melanoma.
24261787 - Recurrence risk after ivor lewis oesophagectomy for cancer.
23027037 - Reviewing the role of parametrial boost in patients with cervical cancer with clinicall...
21493327 - Cetuximab therapy for head and neck squamous cell carcinoma: a systematic review of the...
1696157 - Oropharynx carcinoma: irradiation alone versus induction chemotherapy plus irradiation-...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Expert review of anticancer therapy     Volume:  13     ISSN:  1744-8328     ISO Abbreviation:  Expert Rev Anticancer Ther     Publication Date:  2013 May 
Date Detail:
Created Date:  2013-04-26     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  101123358     Medline TA:  Expert Rev Anticancer Ther     Country:  England    
Other Details:
Languages:  eng     Pagination:  559-67     Citation Subset:  IM    
Oncology Outpatient, Lanesborough Wing, St. George's Hospital, Blackshaw Road, SW17 0QT, UK.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Update on non-melanoma skin cancer and the value of dermoscopy in its diagnosis and treatment monito...
Next Document:  Enhancing radiation therapy for patients with glioblastoma.